CoChat

Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

Open access
Wu, Meng-Ju, Shi, Lei, Dubrot, Juan, Merritt, Joshua, Vijay, Vindhya, Wei, Ting-Yu, Kessler, Emily, Olander, Kira E., Adil, Ramzi, Pankaj, Amaya, Tummala, Krishna Seshu, Weeresekara, Vajira, Zhen, Yuanli, Wu, Qibiao, Luo, Meiqi, Shen, William, García-Beccaria, María, Fernández-Vaquero, Mirian, Hudson, Christine, Ronseaux, Sebastien, Sun, Yi, Saad-Berreta, Rodrigo, Jenkins, Russell W., Wang, Tong, Heikenwälder, Mathias, Ferrone, Cristina R., Goyal, Lipika, Nicolay, Brandon, Deshpande, Vikram, Kohli, Rahul M., Zheng, Hongwu, Manguso, Robert T., Bardeesy, Nabeel · 2022 · Cancer Discovery
Cited by 155

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1-driven genetically engineered mouse models, we show that mIDH1 supports cholangiocarcinoma tumor maintenance through an immunoevasion program centered on dual (R)-2-hydroxyglutarate–mediated mechanisms: suppression of CD8+ T-cell activity and tumor cell–autonomous inactivation of TET2 DNA demethylase. Pharmacologic mIDH1 inhibition stimulates CD8+ T-cell recruitment and interferon γ (IFNγ) expression and promotes TET2-dependent induction of IFNγ response genes in tumor cells. CD8+ T-cell depletion or tumor cell–specific ablation of TET2 or IFNγ receptor 1 causes treatment resistance. Whereas immune-checkpoint activation limits mIDH1 inhibitor efficacy, CTLA4 blockade overcomes immunosuppression, providing therapeutic synergy. The findings in this mouse model of cholangiocarcinoma demonstrate that immune function and the IFNγ–TET2 axis are essential for response to mIDH1 inhibition and suggest a novel strategy for potentiating efficacy. Significance: Mutant IDH1 inhibition stimulates cytotoxic T-cell function and derepression of the DNA demethylating enzyme TET2, which is required for tumor cells to respond to IFNγ. The discovery of mechanisms of treatment efficacy and the identification of synergy by combined CTLA4 blockade provide the foundation for new therapeutic strategies. See related commentary by Zhu and Kwong, p. 604. This article is highlighted in the In This Issue feature, p. 587

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-1077

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 155

Metadata

Authors
Wu, M.-J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., Tummala, K. S., Weeresekara, V., Zhen, Y., Wu, Q., Luo, M., Shen, W., García-Beccaria, M., Fernández-Vaquero, M., Hudson, C., Ronseaux, S., Sun, Y., Saad-Berreta, R., Jenkins, R. W., Wang, T., Heikenwälder, M., Ferrone, C. R., Goyal, L., Nicolay, B., Deshpande, V., Kohli, R. M., Zheng, H., Manguso, R. T., & Bardeesy, N.
Venue
Cancer Discovery
Published
2022-03-01
Volume
12
Issue
3
Pages
812-835
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3216975053
Cited by
155
References
34
FWCI
19.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-1077
The paper
Wu, M.-J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., Tummala, K. S., Weeresekara, V., Zhen, Y., Wu, Q., Luo, M., Shen, W., García-Beccaria, M., Fernández-Vaquero, M., Hudson, C., . . . Bardeesy, N. (2022). Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-1077

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.